News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, the firm said.
Individuals identified as needing homozygous FH evaluation will receive confirmatory genetic testing from Invitae and genetic counseling from Genome Medical.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
In a hospital setting, 1 in 20 patients had cardiac troponin levels above the cut off for diagnosing a heart attack, including patients with no clinical signs of one.
The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.
